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Abstract
MDS are characterized by anemia and transfusion requirements. Transfused patients 
frequently show iron overload that negatively affects hematopoiesis. Iron chelation 
therapy can be effective in these MDS cases, but the molecular consequences of 
this treatment need to be further investigated. That is why we studied the molecular 
features of iron effect and Deferasirox therapy on PI-PLCbeta1 inositide signaling, 
using hematopoietic cells and MDS samples. At baseline, MDS patients showing a 
positive response after iron chelation therapy displayed higher levels of PI-PLCbeta1/
Cyclin D3/PKCalpha expression. During treatment, these responder patients, as well 
as hematopoietic cells treated with FeCl3 and Deferasirox, showed a specific reduc-
tion of PI-PLCbeta1/Cyclin D3/PKCalpha expression, indicating that this signaling 
pathway is targeted by Deferasirox. The treatment was also able to specifically de-
crease the production of ROS. This effect correlated with a reduction of IL-1A and 
IL-2, as well as Akt/mTOR phosphorylation. In contrast, cells exposed only to FeCl3 
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1 |  INTRODUCTION
Nuclear phosphoinositide signaling is implicated in cell pro-
liferation and differentiation.1-3 Among nuclear inositides, 
PI-PLCbeta1 is essential for G1/S transition,4-6 through ac-
tivation of Cyclin D3 or Diacylglycerol,7,8 and is implicated 
in G2/M progression, via Cyclin B1 and PKCalpha.9,10 The 
modulation of PI-PLCbeta1 is differentially associated with 
hematopoiesis in some hematological diseases, such as 
MDS.11-13 In fact, not only PI-PLCbeta1 expression in MDS 
cells is usually increased during myeloid differentiation and 
is reduced during erythropoiesis,14,15 but also PI-PLCbeta1 
downstream targets are affected. In fact, Cyclin D3 is fre-
quently linked to myeloid induction,16 whereas the nuclear 
translocation of PKCalpha is associated with MDS cell cycle 
arrest and erythroid differentiation.17 Moreover, PI-PLCbeta1 
is interconnected with Akt/mTOR pathway, whose activation 
is usually linked to leukemogenesis.12
Phosphoinositides are strictly correlated with oxidative 
stress, which can be relevant in cancer, as tumor progres-
sion is often accompanied by an increase in ROS and the 
subsequent DNA damage.18,19 When used as source of oxi-
dative stress, H2O2 is indeed able to induce the synthesis of 
Phosphatidylinositol-5-phosphate, that becomes a redox-reg-
ulated second messenger via Phosphatidylinositol-5-
phosphate 4-kinase, possibly affecting chromatin structure or 
Peptidyl-prolyl cis-trans isomerase NIMA-interacting 1 ex-
pression.20,21 Moreover, ROS formation is associated with an 
accumulation of Phosphatidylinositol-(3,4,5)-trisphosphate,22 
whose function is related to Phosphatidylinositol-3-kinase, 
that in turn can activate an oxidant-dependent downstream 
signaling pathway. In fact, low concentrations of H2O2 can 
regulate cell proliferation or induce mitogenic signaling, by 
inactivation of Phosphatase and tensin homolog or phosphor-
ylation of Akt.23
As for PI-PLCbeta1, it localizes within the nuclear speck-
les,13 where also Nox4 can be detected,24 possibly regulating 
ROS signaling, especially in MDS. On the one hand, inhibi-
tion of Nox4 activity induces a decline of nuclear ROS pro-
duction.19 On the other hand, Nox4 co-immunoprecipitates 
with Matrin 3, a DNA/RNA protein which controls gene 
expression through interactions with chromatin remodeling.25 
Matrin 3 could, in particular, be a docking site where nu-
clear ROS signaling may exert its function on transcription/
pre-mRNA modulation in specific nuclear domains, such as 
speckles. Moreover, as Nox4 interacts with Akt pathways,26 
and ROS themselves are associated with PKCalpha signal-
ing,27 the ROS-dependent nuclear inositide dysregulation 
could be associated with MDS pathogenesis.19
MDS are characterized by ineffective hematopoiesis and 
cytopenia. Most patients with MDS, at some point in the 
course of their disease, may require transfusions of RBCs to 
correct anemia. However, RBCs transfusions contain high 
levels of iron and the body has no mechanisms to excrete the 
excess of iron.28 Excessive iron can then deposit in the tis-
sues and organs, including the liver, heart, endocrine organs, 
and bone marrow, thus leading to organ damage. Moreover, 
iron overload may be correlated with malignant progression 
or with a suppressive effect on MDS hematopoiesis, which 
is due to the capability of iron-dependent ROS to induce 
abnormal cell death of both erythroid progenitors and mes-
enchymal stem cells.29,30 Increased oxidative stress due to 
RBCs transfusions is, therefore, a molecular feature of trans-
fusion-dependent MDS,31-33 that is why iron must be finely 
regulated in these patients. ICT is referred to drugs that bind 
circulating and cellular non-transferrin bound iron, removing 
deposited iron to convert it in a non-toxic molecule and in 
a form that can be excreted by the body. A consistent, and 
initially surprising, observation in clinical studies of ICT in 
MDS is that a significant minority of patients show a clear 
HI after ICT. These MDS patients also display a reduction 
of serum ferritin levels and RBCs transfusion requirements 
that can lead to transfusion independence.34-36 However, not 
all MDS patients respond to ICT so brilliantly, and neither all 
features of iron physiology nor their role in MDS subtypes 
are completely understood. Therefore, a better clarification 
of the molecular mechanisms underlying ICT or the detection 
of new molecular markers able to identify which patients are 
more or less likely to experience HI with ICT would be help-
ful in clinical practice.
Among the drugs that can be used for ICT, DFX showed 
the ability to improve erythropoiesis, by suppressing ROS 
and cells from MDS patients refractory to Deferasirox showed a specific increase of 
ROS and PI-PLCbeta1/Cyclin D3/PKCalpha expression. All in all, our data show that 
PI-PLCbeta1 signaling is a target for iron-induced oxidative stress and suggest that 
baseline PI-PLCbeta1 quantification could predict iron chelation therapy response in 
MDS.
K E Y W O R D S
deferasirox, inositides, reactive oxygen species
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production, and to induce HI in about 20% MDS patients.36 
Moreover, DFX can specifically affect NFkB expression in 
human K562 erythroleukemia cells and in MDS patients.37 
In fact, NFkB can be inhibited by 50 μM DFX, but not by 
either Deferoxamine or Deferiprone,37 that is, the other two 
iron chelators frequently used in clinical practice, that usually 
show lower rates of HI compared to DFX.28 Other molecular 
pathways that may be relevant to DFX effect include mTOR 
signaling, which is important to start protein translation and 
regulate cell proliferation. Interestingly, upstream mTOR is 
Akt, and the Akt/mTOR axis has already been associated 
with PI-PLCbeta1/Cyclin D3/PKCalpha signaling in MDS.38
Stemming from these data, here we further investigated 
the role of DFX therapy in hematopoietic cell lines and in 
MDS cells, focusing on the effect of DFX on oxidative stress 
and analyzing the behavior of PI-PLCbeta1, along with its 
downstream targets Cyclin D3 and PKCalpha. In addition, 
we tested whether DFX modifies cytokine secretion and Akt/
mTOR activation.
2 |  MATERIALS AND METHODS
2.1 | Antibodies and reagents
The following antibodies and reagents were purchased 
from commercial sources. Rabbit anti-PI-PLCbeta1 
(#PA5-78439) was from Invitrogen (Waltham, MA, USA), 
while mouse anti-beta-Actin (#A1978) was from Sigma-
Aldrich (St. Louis, MO, USA). Rabbit anti-PKCalpha 
(#2056), mouse anti-Cyclin D3 (#2936), rabbit anti-Akt 
(#9272), rabbit anti-phosphorylated-Akt (Ser473, #4058), 
rabbit anti-mTOR (#2983), rabbit anti-phosphorylated-
mTOR (Ser2448, #2971), and the Phototope-HRP Western 
Blot Detection System (#7071) were from Cell Signaling 
Technologies (Danvers, MA, USA). Fluorescein isothio-
cyanate (FITC)-conjugated mouse monoclonal to CD71 
was from Santa Cruz Biotechnology (Dallas, TX, USA). 
Secondary antibodies were HRP-conjugated anti-rabbit 
IgG (#31460, Thermo Fisher, Waltham, MA, USA), HRP-
conjugated anti-mouse IgG (#32430, Thermo Fisher), 
Alexa Fluor 488-conjugated F(ab’)2 fragment of goat anti-
mouse IgG (#4408, Cell Signaling Technologies) and Alexa 
Fluor 488-conjugated F(ab’)2 fragment of goat anti-rabbit 
IgG (#4412, Cell Signaling Technologies). Deferasirox 
(DFX, #D228650, Toronto Research Chemicals Canada) 
and FeCl3 (Sigma-Aldrich) were also purchased.
2.2 | Tissue cell cultures
H9C2 rat cardiomyocytes were grown at 37°C with 5% 
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VA, USA) supplemented with 10% heat-inactivated fetal 
bovine serum, L-glutamine, and streptomycin/penicillin 
(Corning). Erythroleukemia K562 and monocytic THP-1 
cell lines were grown at 37°C with 5% CO2 in RPMI 1640 
medium (Cambrex BioScience, Baltimore, MD, USA) sup-
plemented with 10% heat-inactivated fetal bovine serum, 
L-glutamine and streptomycin/penicillin (Corning) at an 
optimal cell density of 0.3  ×  106 to 0.8  ×  106  cells/mL. 
K562 and THP-1 cell lines were treated with 150 µM FeCl3 
for 48  hours and DFX 50  µM for 6  hours, used alone or 
in combination. The in vitro concentration of DFX was 
used to imitate in vitro the patients' dose. It was calculated 
considering the common dose range of 10-20  mg/kg/die 
given to MDS patients. This dose can be increased up to 
40 mg/kg or reduced to 5 mg/kg, according to the patient's 
need.39 The equivalence between DFX dose and molarity 
was then calculated considering that the mean weight of 
1 mL blood is 1.06 g 40 and that the DFX molecular weight 
is 373.362 g/mol. This means that the range 5-40 mg/Kg is 
equal to 14-107 µM. Moreover, pharmacokinetics studies41 
showed that DFX plasma levels are maintained within the 
therapeutic range over a 24-hour period (20 mg/kg/die give 
a peak range of 60-100 µmol/L). Therefore, our in vitro ex-
periments were based on the most common dose of 20 mg/
kg/die given to our case series. We used a concentration 
of 50 µM because the same concentration was also used in 
K562 cells to investigate NFkB signaling and was proven 
to be effective in K562 experimental model.37
2.3 | Patient characteristics, treatment, and 
evaluation of response
BM samples were obtained from six transfusion-depend-
ent MDS patients treated with DFX and six healthy sub-
jects who had given informed consent according to the 
Declaration of Helsinki (Table 1). All samples came from 
the Institute of Hematology “L e A Seràgnoli,” University 
of Bologna, Bologna, Italy. The diagnosis was defined 
according to the 2008 WHO classification42 and, accord-
ing to the International prognostic scoring system,43 pa-
tients were divided into low risk (n  =  5) or intermediate 
risk (n  =  1). Response to treatment and the clinical out-
come were evaluated according to the revised International 
Working Group response criteria.44 Before the therapy, all 
patients were transfusion-dependent (ie, requiring ≥1 unit 
of packed RBCs in ≤8 weeks averaged over 4 months be-
fore the start of treatment) and had a serum ferritin level 
≥1000  ng/mL.34 Patients were treated with the iron che-
lator DFX (oral administration), with a 10-20  mg/kg/die 
starting dose range that could be personalized according to 
their blood transfusion frequency, with the aim to reduce 
transfusion-dependent iron overload.34
2.4 | Isolation of mononuclear cells
For in vitro experiments, BM mononuclear cells (MNCs) 
were isolated at baseline and during therapy by Ficoll-Paque 
density-gradient centrifugation (Amersham Biosciences, 
Uppsala, Sweden), according to the manufacturer's instruc-
tions. All analyses were performed on samples from patients 
at the time of diagnosis and during the therapy.
2.5 | Illumina next generation sequencing
The mutational profile of 32 recurrently mutated genes in 
myeloid malignancies was determined using an Illumina 
TruSeq Custom Amplicon next-generation sequencing 
gene panel and the TruSeq Amplicon 2.0 BaseSpace app 
workflow45 (Illumina, San Diego, CA, USA), as previously 
described.46
2.6 | Gene and protein expression analysis
Total RNA was extracted from cell lines and patients' sam-
ples. RNA was retro-transcribed and the expression of PI-
PLCbeta1, Cyclin D3 and PKCalpha genes was assessed 
using a standard TaqMan Real-Time PCR method (Applied 
Biosystems, Foster City, CA, USA), with the Glyceraldehyde 
3-phosphate dehydrogenase TaqMan probe as the endog-
enous control and a pool of healthy subjects as an internal 
control, as previously reported.47 Protein amount was quanti-
fied on hematopoietic cell lines by Western Blot analyses, 
using beta-Actin as a control of equal protein loading, as 
already described,16 and immunocytochemistry. For MDS 
samples, as the number of patients' cells was limited, protein 
expression was determined by immunocytochemistry only, 
as previously illustrated.15
2.7 | Flow cytometric analysis of cell 
cycle and apoptosis
Cell cycle distribution of hematopoietic cell lines was ex-
amined according to Poli et al,17 while apoptosis was quan-
tified by staining with Annexin V/Alexa Fluor 488 and PI, 
following the manufacturer's instructions (Alexa Fluor 488 
Annexin V/Dead cell apoptosis kit; #V13245, Invitrogen). 
The percentage of apoptotic cells was also detected on a 
PI histogram (FL3lin/count) as a hypo-diploid peak using 
a suitable acquisition software (CXP Cytometer, Beckman 
Coulter, Brea, CA, USA) and a proper software analysis 
(CXP Analysis, Beckman Coulter). For a more accurate 
evaluation of primary necrotic cells, non-permeabilized 
Annexin-V stained cells were counter-stained with PI.
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2.8 | Flow cytometric detection of CD71 levels
For the detection of CD71 surface antigen, K562 cells were 
cultivated in RPMI medium (Cambrex Bio Science) and 
H9C2 cells in DMEM-high glucose (Corning). The percent-
age of positive cells was quantified using an FC500 Dual 
Laser Flow Cytometer with the appropriate software (System 
II, Beckman Coulter), as reported elsewhere.17 At least 
10 000 events/sample were acquired.
2.9 | Flow cytometric analysis of 
ROS production
Intracellular ROS production was monitored by oxidation of a 
fluorescein reduced derivative probe, used as living cell-per-
meant indicator (H2-DCFDA; #C400, Invitrogen). Under the 
influence of intracellular esterases, this probe becomes sensi-
tive to ROS-induced oxidation, resulting in an increased green 
fluorescence, detectable by a flow cytometer equipped with a 
488 nm Argon Laser as excitation source and appropriate filters 
for fluorescein isothiocyanate (emission on wavelength 517-
527 nm). At first, 8 × 105 K562 or THP-1 cells were incubated 
with FeCl3 for 48 hours (FeCl3) or left untreated (CTRL). Then, 
to remove RPMI Medium's Red Phenol and any iron residues 
(that can virtually interfere with intensity of fluorescent sig-
nal), samples were briefly centrifuged (1200 rpm × 8 minutes), 
washed twice in 1x phosphate buffered saline, resuspended in 
1 mL of 1x phosphate buffered saline and added with 5 µM 
H2-DCFDA. For both CTRL and FeCl3 cells, we collected four 
samples with 8 × 105 cells each: one to assess the cells' auto-
fluorescence (AUTO, to be used as an internal control), one to 
evaluate the baseline ROS activity (CTRL or FeCl3), one to be 
used as a positive control of ROS production (H2O2, with cells 
treated with15 µM H2O2 for 5 hours) and one to test the ef-
fect of treatment (DFX, with cells treated with 50 µM DFX for 
6 hours). For the autofluorescence samples, a natural-baseline, 
not probe-induced, green fluorescence was used. CTRL and 
FeCl3 samples were incubated at 37°C for 10 minutes, to induce 
the probe to enter the cells. After this probe-loading phase, cells 
were treated with DFX and/or with H2O2. Samples were then 
incubated for 6 hours in the dark at 37°C before undergoing the 
cytofluorimetric analysis. To ensure the correct incoming of the 
probe in cells, the FL1 green photomultiplier voltage was set to 
have the autofluorescence signal within the first scale decade 
(log scale), so that the ROS basal production appeared as a his-
togram's right-shift of at least 2.5 decades.
2.10 | Cytokine secretion
The profile of multiple cytokines secreted by stimulated cells 
was tested using the Multi-Analyte ELISArray Kit (Qiagen, 
Venlo, The Netherlands), according to the manufacturer's 
instructions.
2.11 | Statistical analyses
All the analyses were performed using the GraphPad Prism 
Software (v.4.0, La Jolla, CA, USA). Dunnett's test post-
analysis of variance was used to compare continuous values 
and paired Student t test was used to compare paired groups. 
Tests were considered statistically significant when the P-
value was <.05.
3 |  RESULTS
3.1 | Effect of FeCl3 on K562 and THP-1 cell 
cytotoxicity
To determine the right concentration of FeCl3 for our experi-
mental model, a dose response analysis on K562 and THP-1 
cells was performed, and an Annexin V/PI evaluation was 
carried out (Figure 1). Since previous works on cardiac cells 
showed that the oxidative effect of FeCl3 was detectable after 
treatment with 150 µM for 48 hours,48 we also started with a 
48 hours treatment and with doses under and above 150 µM. 
In K562 cells (Figure 1A,C), FeCl3 150 µM for 48 hours was 
able to induce a mild early apoptosis (5.9% of Annexin V+/
PI- cells), a mild late apoptosis (2.6% of Annexin V+/PI+ 
cells) and a mild necrosis (2.2% of Annexin V-/PI+ cells). At 
lower concentrations (100 µM) there was no statistical dif-
ference with control cells, whereas at higher concentrations 
(1 mM and 5 mM), both apoptotic and necrotic fractions in-
creased. In contrast, as shown in Figure 1B,D, THP-1 cells 
seemed to be significantly affected only by high concentra-
tions of FeCl3 (ie, 5 mM).
3.2 | Effect of FeCl3 and DFX on K562 and 
THP-1 cell cycle and apoptosis
To mimic the iron accumulation induced by transfusions, 
K562 and THP-1 cells were treated with 150 µM FeCl3 for 
48 hours, while DFX was used at a concentration of 50 µM 
for 6 hours.
Cells were treated with FeCl3 and DFX alone or in com-
bination, and both cell cycle and Annexin V/PI analyses were 
performed (Figures S1 and S2). In both cell lines, the selected 
doses of FeCl3 and DFX did not have significant effects on 
cell cycle or apoptosis. Indeed, in K562 cells, FeCl3, alone or 
in combination with DFX, was able to induce a small increase 
in the number of sub-G0/G1 cells (4.2% FeCl3/FeCl3 + DFX 
vs 2.0% CTRL), while all of the other cell cycle phases were 
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not significantly different from the untreated cells. In contrast, 
DFX alone induced a prominent G0/G1 arrest (49.6% DFX vs 
36.0% CTRL), that was not detectable in K562 cells after the 
combination treatment (Figure S1A,C). As for Annexin V/PI 
analyses, neither FeCl3 nor DFX, used alone or in combination, 
were able to induce a major change in apoptotic or necrotic 
cells (Figure S1B,D). In fact, the early apoptotic (Annexin 
V+/PI-) fractions showed a minimal reduction only in K562 
cells treated with DFX (2.3% DFX vs 4.3% CTRL), while both 
FeCl3 alone and the combination treatment showed compara-
ble levels of early apoptotic cells (4.2% and 5.2%, respectively, 
vs 4.3% CTRL). Moreover, only in FeCl3-treated cells, the ne-
crotic (Annexin V-/PI+) fraction increased more than the other 
samples, although not reaching a statistically significant differ-
ence (3.9% FeCl3 vs. 1.4% CTRL). Conversely, although DFX, 
in combination with FeCl3, was able to induce a mild, not sta-
tistically significant, increase of the THP-1 early apoptotic cell 
fraction (Figure S2B,D), this was not correlated to substantial 
changes in cell cycle profile (Figure S2A,C).
3.3 | Effect of FeCl3 and DFX on 
induction of ROS in K562 and THP-1 cells
To examine the effect of FeCl3 and DFX on oxidative stress, 
we optimized a flow cytometric-based test (Figures 2 and 3), 
F I G U R E  1  Effect of FeCl3 exposition on cytotoxicity of K562 and THP-1 cells. Flow cytometric analysis of (A) K562 and (B) THP-1 cells 
stained with Annexin V/PI after exposition of 48 hours with increasing doses of FeCl3 for up to 5 mM (as indicated). Dot plots report the cell 
percentage for each quadrant. In K562 cells, FeCl3 150 µM for 48 hours was able to induce a mild early apoptosis (5.9% of Annexin V+/PI- cells), 
a mild late apoptosis (2.6% of Annexin V+/PI+ cells) and a mild necrosis (2.2% of Annexin V-/PI+ cells). In contrast, THP-1 cells seemed to 
be significantly affected only by high concentrations of FeCl3 (ie, 5 mM). Percentage of PI+/Annexin V- cells are indicated in upper left corner; 
PI+/Annexin V+: upper right corner; PI-/Annexin V+: lower right corner; PI-/Annexin V-: lower left corner. Representative data of at least three 
independent experiments. C, Statistical analysis of Annexin V/PI results in K562 cells show that there is a statistically significant difference in 
Annexin V-/PI- fractions and Annexin V+/PI- fractions only after treatment with FeCl3 1mM and 5mM, as compared with CTRL cells (**P < .01 vs 
CTRL), whereas in (D) THP-1 cells there is a statistically significant difference in Annexin V-/PI- fractions and Annexin V+/PI- fractions only after 
treatment with FeCl3 5mM, as compared with CTRL cells (**P < .01 vs CTRL). Data are representative of at least three independent experiments
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using autofluorescence (AUTO) as a reference marker 
(Figures 2G and 3G). At first, we compared the ROS production 
in K562 untreated samples (CTRL, Figure 2A) with cells treated 
with FeCl3 only (FeCl3, Figure 2B), finding out that the FeCl3 
stimulus was able to increase the ROS production by about 14% 
(38.82% CTRL vs 53.02% FeCl3). Instead, DFX was able to 
reduce the ROS production in both CTRL cells (38.82% CTRL 
vs 0.05% DFX, Figure 2C) and in FeCl3-treated cells (53.02% 
FeCl3 vs 0.58% FeCl3 + DFX, Figure 2D). Interestingly, the de-
crease in ROS production was higher in FeCl3-pretreated cells, 
as the difference corresponded to 52.44%, while in CTRL cells 
it was reduced by 38.77%. Finally, the exposition to H2O2 rep-
resented the positive control in both experimental conditions, as 
H2O2 was able to induce the ROS production by about 60% in 
the CTRL samples (38.82% CTRL vs 99.01% H2O2, Figure 2E) 
and by about 45% in the FeCl3-treated cells (53.02% FeCl3 vs 
98.39% FeCl3 + H2O2, Figure 2F).
In THP-1 cells, FeCl3 was not able to induce ROS pro-
duction, rather the opposite: FeCl3 was indeed associated 
with a decrease of ROS production (51.40% CTRL vs 
38.00% FeCl3, Figure  3A,B). Even DFX was able to re-
duce the ROS production, in both CTRL (51.40% CTRL 
vs 0.20% DFX, Figure 3C) and FeCl3-treated cells (38.00% 
FeCl3 vs 5.50% FeCl3  +  DFX, Figure  3D). As shown in 
Figure 3E,F, the exposition to H2O2 represented the positive 
control in both experimental conditions, as H2O2 was able 
to induce the ROS production by about 45% in the CTRL 
samples (51.40% CTRL vs 97.10% H2O2, Figure 3E) and 
by about 60% in the FeCl3-treated cells (38.00% FeCl3 vs 
98.70% FeCl3 + H2O2, Figure 3F).
As a further control, we also tested the effect of three 
concentrations of DFX in CTRL and H2O2-treated K562 
cells, using the autofluorescence (AUTO) as a reference 
(Figure S3G). Again, DFX was able to reduce the ROS pro-
duction in a dose-dependent manner, although there was no 
significant difference between DFX 50 and 75 µM (Figure 
S3A,C,E). In contrast, increasing doses of DFX added to 
H2O2 were only able to partially affect H2O2-induced ROS 
F I G U R E  2  Effect of FeCl3 and DFX exposition on ROS production of K562 cells. The ROS production in (A) K562 untreated samples 
(CTRL) was compared with (B) cells pre-treated with FeCl3 only (FeCl3). FeCl3 is able to induce the ROS production by about 14% (53.02% CTRL 
vs 38.82% FeCl3). DFX reduces the production of ROS in both samples: in (C) CTRL cells, ROS production was reduced by 38.77%, while in (D) 
FeCl3-pretreated cells the difference corresponded to 52.44%. (E, F) H2O2 induces ROS production in both samples. Representative data of at least 
three independent experiments. (G) Autofluorescence graph (AUTO), used as a reference marker for all analyses. (H) Statistical analysis of ROS 
production in K562 cells (*P < .05; **P < .01). Data are representative of at least three independent experiments
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production (Figure S3B,D,F). This was evident from the 
analysis of the mean fluorescence intensity reported in 
Figure S3H. Finally, also the expression of the CD71 sur-
face marker was analyzed during DFX treatment, but no 
significant changes were detected among the different con-
centrations tested, while all K562 samples showed a CD71 
percentage significantly higher than both autofluorescence 
(AUTO), used as a reference marker, and H9C2 cells, rep-
resenting our negative control (Figure 4).
3.4 | Effect of FeCl3 and DFX on gene and 
protein expression of PLCbeta1/Cyclin D3/
PKCalpha signaling in K562 cells
As Figure 5A shows, the amount of PI-PLCbeta1 gene ex-
pression was significantly increased in K562 cells exposed 
to FeCl3, as compared with baseline (Student's t test, P < .05 
vs. baseline, 95% CI +0.08 to +1.19), while it was almost 
constant, or slightly decreased, in K562 cells treated with 
the combination of FeCl3 and DFX, as compared with base-
line (Student's t test, P > .05 vs. baseline, 95% CI −0.52 to 
+0.58). Even Cyclin D3 gene expression showed an increase, 
although not statistically significant, in FeCl3-treated K562 
cells, as compared with baseline (Student's t test, P > .05 vs. 
baseline, 95% CI +0.11 to +0.79), but the combination of 
FeCl3 and DFX showed a statistically significant reduction 
of Cyclin D3 mRNA (Student's t test, P < .05 vs. baseline, 
95% CI −0.20 to −1.11). Finally, even PKCalpha expres-
sion was significantly increased in K562 cells treated with 
FeCl3 (Student's t test, P < .05 vs. baseline, 95% CI +0.37 
to +2.97), while K562 cells exposed to the combination 
treatment showed a slight decrease, as compared with base-
line (Student's t test, P > .05 vs. baseline, 95% CI −1.02 to 
+1.57). Protein expression analysis confirmed the mRNA 
behavior: PI-PLCbeta1/Cyclin D3/PKCalpha axis was in-
duced in FeCl3-treated cells, while the treatment with DFX 
or FeCl3 + DFX resulted in a reduction of protein expression 
F I G U R E  3  Effect of FeCl3 and DFX exposition on ROS production of THP-1 cells. The ROS production in (A) THP-1 untreated samples 
(CTRL) was compared with (B) cells pre-treated with FeCl3 only (FeCl3). FeCl3 is not able to induce ROS production, rather the opposite 
(38.00% CTRL vs 51.40% CTRL + FeCl3). Even DFX and H2O2 treatments are able to induce a response in both samples: (C, D) DFX reduces 
the production of ROS, whereas (E, F) H2O2 induces it. Representative data of at least three independent experiments. G, Autofluorescence graph 
(AUTO), used as a reference marker for all analyses. H, Statistical analysis of ROS production in K562 cells (*P < .05; **P < .01). Data are 
representative of at least three independent experiments
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(Figure  5B-D). As for the inositide localization, all tested 
proteins were mostly cytoplasmic at baseline, and expressed 
both in nucleus and cytoplasm during treatment.
3.5 | Effect of FeCl3 and DFX on cytokine 
secretion in K562 cells
K562 cells were treated with FeCl3 and DFX, alone or in 
combination, and the therapy effect on the expression of 12 
cytokines commonly secreted by hematopoietic cells was ana-
lyzed. As Figure 6A shows, ten cytokines showed similar or not 
statistically significant reducing levels during any treatment, as 
compared with baseline. Conversely, two cytokines were dif-
ferentially expressed during FeCl3 and DFX administration 
(Figure 6B): FeCl3 alone was able to greatly induce both IL-1A 
and IL-2 secretion, while both DFX alone and the combination 
of FeCl3 and DFX induced a reduction of the secretion of these 
cytokines. As Figure 6B shows, this decrease reached a statisti-
cally significant difference only after exposition to DFX alone, 
while it was close to significant after FeCl3 and DFX combina-
tion treatment (P = .05 for IL-1A, P = .06 for IL-2).
3.6 | Effect of FeCl3 and DFX on Akt/
mTOR protein expression in K562 cells
The treatment with DFX, alone or in combination with FeCl3, 
specifically reduced the expression of the phosphorylated 
isoforms of Akt and mTOR, with a more marked decrease 
F I G U R E  4  Effect of DFX on the 
expression of CD71 erythoid-specific 
surface markers in K562 cells. Flow 
cytometric analysis of surface CD71 
expression in K562 cells treated with 
increasing doses of DFX. Representative 
data of at least three independent 
experiments. A, Autofluorescence (AUTO) 
and (B) H9C2 cells were used as a reference 
marker and a negative control, respectively. 
C, Overlay between untreated (CTRL) 
K562 cells and AUTO: 93.38% CTRL 
cells are positive for CD71. D, Overlay 
between K562 cells treated with DFX 
25 µM and AUTO: 93.36% DFX 25 µM 
cells are positive for CD71. E, Overlay 
between K562 cells treated with DFX 
50 µM and AUTO: 93.03% DFX 50 µM 
cells are positive for CD71. F, Overlay 
between K562 cells treated with DFX 
75 µM and AUTO: 94.17% DFX 75 µM 
cells are positive for CD71. G, Statistical 
analysis of CD71 expression in K562 cells 
during treatment (**P < .01). Data are 
representative of at least three independent 
experiments
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in phosphorylated-mTOR. In contrast, FeCl3 alone was able 
only to marginally induce the specific activation of both 
proteins, as compared with the untreated (CTRL) cells. The 
total proteins were not affected, and Beta-Actin was used as 
a loading control (Figure 6C).
3.7 | Patient outcomes and gene 
mutation status
Between April 2006 and December 2019, six patients 
with lower risk MDS started ICT with DFX. They were 
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transfusion-dependent (median number of RBC units at 
baseline: 58) and showed a baseline median ferritin level 
of 2250.5 ng/mL (range 1547-3770 ng/mL). With a median 
follow-up of 40.5 months (range 2-99 months), three patients 
showed a significant improvement of hematopoiesis (de-
fined as HI, according to the International Working Group 
response criteria44). Following hematologic response, these 
patients also became transfusion independent and continued 
DFX until the achievement of a serum ferritin level <500 ng/
mL. In contrast, the other three patients did not show any HI 
and remained transfusion-dependent during DFX administra-
tion, thus showing a persistently high ferritin level (Table 1).
Next generation sequencing analysis carried out on sam-
ples at baseline (Table 1) are in accordance with a recent anal-
ysis where no single baseline gene mutation was predictive of 
HI, but the mutation number was lower in DFX responders 
compared to resistant patients.49
3.8 | PI-PLCbeta1, Cyclin D3, and 
PKCalpha gene and protein expression levels in 
MDS patients treated with DFX
At baseline, the level of PI-PLCbeta1, Cyclin D3, and 
PKCalpha mRNA in BMMNCs from three patients who 
subsequently showed a hematologic response after ICT (ie, 
responders) was higher as compared with non-responders 
and with a pool of healthy subjects (Figure 7A). During DFX 
therapy, the amount of PI-PLCbeta1 mRNA significantly in-
creased in non-responder patients, as compared with baseline 
(Student's t test, P < .05 vs. baseline, 95% CI +1.39 to +2.27), 
while in responder patients it remained substantially un-
changed (Student's t test, P > .05 vs. baseline, 95% CI −0.20 
to +0.52). Cyclin D3 gene expression showed a similar be-
havior: during DFX therapy, Cyclin D3 mRNA significantly 
increased in non-responder patients, as compared with base-
line (Student's t test, P < .05 vs. baseline, 95% CI +0.10 to 
+2.00), while responder patients showed an almost constant 
Cyclin D3 level (Student's t test, P > .05 vs. baseline, 95% 
CI −0.95 to +0.73). Finally, even PKCalpha significantly 
increased only in non-responder patients (Student's t test, 
P  <  .05 vs. baseline, 95% CI +2.40 to +2.92), while re-
sponder patients showed a decrease, although not statisti-
cally significant (Student's t test, P > .05 vs. baseline, 95% 
CI −0.72 to −0.30). Protein expression analysis confirmed 
the mRNA behavior: after ICT, PI-PLCbeta1, Cyclin D3, and 
PKCalpha expression were highly induced in non-responder 
subjects, while the same proteins did not significantly change 
in responder patients (Figure 7B-D). Moreover, all analyzed 
proteins seemed to show a localization change during ther-
apy, that was more evident for PKCalpha, which seemed to 
be localized both in nucleus and cytoplasm during therapy.
4 |  DISCUSSION
Nuclear inositide-dependent signaling is finely regulated in 
the hematopoietic system and is involved in MDS patho-
genesis, through genetic and epigenetic processes.50-52 PI-
PLCbeta1 is particularly implicated in cell cycle regulation 
and differentiation, via Cyclin D3 and PKCalpha. Moreover, 
given its nuclear co-localization with Nox4,24 PI-PLCbeta1 
could play a relevant role in oxidative stress.
MDS patients are frequently dependent on blood transfu-
sions. This can lead to an exogenous iron overload that may 
be highly cytotoxic, through the production of ROS. That is 
why MDS patients requiring blood transfusions need to be 
treated with iron chelators, that is, DFX. Although the mech-
anism of action of DFX is well known (two molecules of 
DFX bind one molecule of Fe3+ to form a stable complex 
which is eliminated via the kidneys), the molecular effects of 
ICT are still not fully clarified.
That is why in this study we examined more in detail 
the molecular mechanisms underlying the effect of DFX on 
PI-PLCbeta1 signaling, using both hematopoietic cells and 
MDS samples as experimental models. At first, we tested 
K562 and THP-1 cells, that is, a erythroleukemia cell line 
that has been recently used to analyze the effect of DFX53 and 
a monocytic cell line often used in inositide studies. We did 
not test any other erytholeukemia cell line, as other papers 
F I G U R E  5  Gene and protein expression of PI-PLCbeta1, Cyclin D3, and PKCalpha in K562 cells during FeCl3 and DFX exposition. K562 
cells were treated with 150 µM FeCl3 for 48 hours and/or 50 µM DFX for 6 hours. A, The amount of PI-PLCbeta1, Cyclin D3 and PKCalpha 
gene expression increases in K562 cells exposed to FeCl3 (FeCl3), as compared with baseline (CTRL), while it is almost constant, or decreased, 
in K562 cells treated with DFX (DFX) or the combination of FeCl3 and DFX (FeCl3 + DFX), as compared with baseline (CTRL). Data are 
representative of at least three independent experiments (*P < .05; **P < .01). B, Representative immunocytochemical analysis of PI-PLCbeta1 
protein expression (green signal) in K562 cells during FeCl3 and DFX treatment. Only FeCl3-treated cells show an increase of protein expression 
during therapy. Original magnification ×600. Nuclei are visualized by DAPI staining (blue signal). At least 10 different fields were observed. 
C, Representative immunocytochemical analysis of Cyclin D3 protein expression (green signal) in K562 cells during FeCl3 and DFX treatment. 
Original magnification ×600. Nuclei are visualized by DAPI staining (blue signal). Only FeCl3-treated cells show an increase of protein expression 
during therapy. D, Representative immunocytochemical analysis of PKCalpha protein expression (green signal) in K562 cells during FeCl3 and 
DFX treatment. Only FeCl3-treated cells show an increase of protein expression during therapy. Original magnification ×600. Nuclei are visualized 
by DAPI staining (blue signal). At least 10 different fields were observed
   | 15411CAPPELLINI Et AL.
F I G U R E  6  Effect of FeCl3 and DFX on cytokine secretion and Akt/mTOR protein expression in K562 cells. K562 cells were treated with 
150 µM FeCl3 for 48 hours (FeCl3) or 50 µM DFX for 6 hours (DFX) alone, or in combination (FeCl3 + DFX), and the therapy effect on the 
secretion of 12 cytokines was analyzed and compared with untreated (CTRL) cells. A, Ten cytokines show similar or slightly, not statistically 
significant, reduced levels during treatment, while (B) IL-1A and IL-2 are differentially expressed during FeCl3 and DFX administration: FeCl3 
alone is able to induce both cytokines in a statistically significant manner, as compared with untreated cells (CTRL), while DFX, alone or in 
combination with FeCl3, induces a reduction of cytokine secretion. The decrease in IL-1A and IL-2 is statistically significantly only after exposition 
to DFX alone (*P < .05), while it is close to significant after FeCl3 and DFX combination (P = .05 for IL-1A and P = .06 for IL-2). Data are 
representative of at least three independent experiments (*P < .05; **P < .01). C, Protein expression of total and phosphorylated Akt and mTOR 
show that the treatment with DFX alone or the combination of FeCl3 and DFX corresponds to a lower amount of both phosphorylated proteins, as 
compared with the total proteins and the untreated (CTRL) cells. In contrast, FeCl3 alone was able only to marginally induce the specific activation 
of both proteins. Beta-Actin is used as a loading control
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dealing with ROS studies showed similar effects on K562 
and TF-1 cells,54 and because our main interest in this study 
was about the involvement of inositides in oxidative stress 
during DFX therapy. As previous reports showed that the ad-
dition of iron chelators to cell cultures exposed to FeCl3 was 
able to counteract its cytotoxic effect,55 and given that DFX 
has a strong affinity for Fe3+, we used FeCl3 as a source of 
iron, to mimic the effect of MDS iron overload due to RBCs 
transfusions. Our results show that the selected concentra-
tions of FeCl3 and DFX did not significantly affect cell cycle, 
nor apoptosis, in both cell lines. Therefore, we hypothesized 
that the prevalent effect of our experimental conditions was 
on induction of oxidative stress and not of cytotoxicity. That 
is why we then optimized a flow cytometric-based protocol 
aiming to determine the amout of ROS production in our 
cells. When FeCl3-pretreated K562 cells were labeled with 
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H2-DCFDA, which accumulates within the cell and becomes 
fluorescent upon oxidation, there was an increase of 15% in 
ROS production, as compared with untreated cells. In con-
trast, DFX was able to completely reset the ROS production, 
counteracting the FeCl3 effect. Of note, the Delta between 
fluorescence intensity decrease observed in FeCl3-pretreated 
cells after DFX exposition (53.02%  −  0.58%  =  52.44%) 
was higher than the one observed in the untreated samples 
(38.82%  −  0.05%  =  38.77%), so that DFX-induced reduc-
tion of ROS was more marked in FeCl3-pretreated cells. This 
effect was cell line-dependent, as THP-1 cells were not af-
fected. That is why we did not test any inositide signaling or 
gene/protein expression changes with DFX in THP-1 cells, 
and all subsequent analyses were carried out only on K562 
cells. Moreover, the DFX effect on the decrease of ROS was 
not due to a quenching phenomenon, as shown by both ROS 
analysis and CD71 expression during administration of dif-
ferent concentrations of H2O2 and FeCl3, but could probably 
be linked to a direct effect of DFX on ROS production, whose 
functional role is still controversial,56 as well as to a direct 
and non-specific DFX-induced change in the cell oxidative 
status, as reported in neutrophils.57 As for inositide analyses, 
PI-PLCbeta1/Cyclin D3/PKCalpha signaling was increased 
only in FeCl3-treated cells, while it was reduced after exposi-
tion to DFX alone and the combination treatment.
PI-PLCbeta1/Cyclin D3/PKCalpha signaling is intercon-
nected with the Akt pathway, that in turn has been associated 
with ROS and cytokine secretion to regulate inflammation 
and oxidative stress in leukemia.58 That is why we also an-
alyzed autonomous changes in 12 cytokines commonly se-
creted by K562 and hematopoietic stem cells, to see whether 
the ROS production induced by FeCl3 and DFX (that have 
a clear effect on K562 erythroleukemia cells) could also be 
able to change cytokine secretion in the same cells, possibly 
affecting specific inositide targets. In fact, IL-1A can inter-
act with mTOR or activate PKCalpha to regulate ROS pro-
duction,59-61 while IL-2 increases the ROS production and is 
implicated in inositide signaling via Akt/mTOR pathway.62-64 
Our cytokine and protein analysis on K562 cells showed that 
the secretion of IL-1A and IL-2, as well as the level of Akt/
mTOR activation, could be related to a specific response to 
FeCl3 and DFX, thus confirming the involvement of inositide 
pathways in cytokine signaling and DFX response. In fact, al-
though the reduction of IL-1A and IL-2 induced by the com-
bination of DFX and FeCl3 was not statistically significant, 
the cytokine changes can have an important downstream bi-
ological effect on inositide signaling, as shown by the reduc-
tion of Akt and mTOR phosphorylation.
Interestingly, the treatment of our K562 cells with 
FeCl3 alone could imitate the condition of MDS non-re-
sponder patients, where an accumulation of iron is pres-
ent. Conversely, K562 cells treated with FeCl3 and DFX 
could mimic the responder MDS cases, that are subjected 
and positively respond to both iron accumulation and DFX 
therapy. Stemming from these premises, we further ex-
amined PI-PLCbeta1/Cyclin D3/PKCalpha signaling in a 
small series of MDS patients who received ICT with DFX. 
In our case series, a subgroup of subjects showed a favor-
able hematologic response and, consequently, underwent 
the discontinuation of transfusions and a significant reduc-
tion of serum ferritin. In contrast, the remaining patients 
did not show any hematologic response and continued to 
show transfusion-dependence, leading to high levels of 
serum ferritin, likely stimulating iron-induced oxidative 
stress. Our small group of patients was balanced, with 50% 
of responder and 50% of non-responder patients respec-
tively and, although it does not reflect the percentage of re-
sponder patients in the real world setting, it was useful for 
our study to preliminarly perform ex vivo studies on DFX 
effect in a balanced population. Also a mutational analysis 
on our MDS patients at baseline was performed. Our next 
generation sequencing analysis, although obtained from a 
very small number of cases, could not yet predict any ef-
fect of ICT from baseline mutations, but was in accordance 
with a recent study showing that the number of mutations 
at baseline, and not the specific type of gene mutation, cor-
related with response and was lower in DFX responders 
compared to resistant patients.49 Moreover, the same study 
reported that a low number of somatic mutations in bone 
marrow progenitors could contribute also to the positive 
F I G U R E  7  Gene and protein expression of PI-PLCbeta1, Cyclin D3, and PKCalpha in MDS patients during DFX therapy. A, At baseline, 
only responder patients show higher, statistically significant, levels of PI-PLCbeta1, Cyclin D3 and PKCalpha mRNAs, as compared with non-
responder patients and healthy subjects. During DFX therapy, non-responder patients show a statistically significant increase of PI-PLCbeta1, 
Cyclin D3 and PKCalpha gene expression, as compared with baseline and responder patients. Data are representative of at least three independent 
experiments. (*P < .05 vs Healthy Subjects or Baseline; ns: not statistically significant). B, Representative immunocytochemical analysis of 
PI-PLCbeta1 protein expression (green signal) in responder and non-responder MDS patients during DFX therapy. Only non-responders show 
an increase of protein expression during therapy. Original magnification ×600. Nuclei are visualized by DAPI staining (blue signal). At least 10 
different fields were observed. C, Representative immunocytochemical analysis of Cyclin D3 protein expression (green signal) in responder and 
non-responder MDS patients during DFX therapy. Original magnification ×600. Nuclei are visualized by DAPI staining (blue signal). Only non-
responders show an increase of protein expression during therapy. D, Representative immunocytochemical analysis of PKCalpha protein expression 
(green signal) in responder and non-responder MDS patients during DFX therapy. Only non-responders show an increase of protein expression 
during therapy. Original magnification ×600. Nuclei are visualized by DAPI staining (blue signal). At least 10 different fields were observed
15414 |   CAPPELLINI Et AL.
effects of ICT regarding the overall haematopoietic func-
tion in MDS, confirming the positive prognostic effect of a 
lower mutation burden in baseline MDS.49
As for inositides, our findings show that responder MDS 
patients display baseline higher levels of PI-PLCbeta1/
Cyclin D3/PKCalpha mRNAs, as compared with both 
non-responder patients and a pool of healthy subjects. This 
data, even if it has to be confirmed on a larger series of pa-
tients, might be used to identify a subgroup of patients who 
are more likely to show a favorable hematological response 
to ICT. Moreover, after ICT, inositide signaling was clearly 
increased only in non-responder patients, who exhibited 
higher gene and protein expression of PI-PLCbeta1, as well 
as of its downstream targets Cyclin D3 and PKCalpha, all 
associated with cell cycle regulation and oxidative stress. 
In contrast, in responder subjects, the gene and protein ex-
pression of inositide signaling molecules remained almost 
constant after ICT, as compared with baseline. Therefore, 
both the presence of a peculiar molecular gene expression 
profile at baseline and of different patterns of molecular re-
sponse of inositides to DFX hints at a role for PI-PLCbeta1 
and PI-PLCbeta1-dependent signaling as molecular targets 
in iron-induced oxidative stress. Although apparently the 
gene expression changes in MDS responder patients appear 
to be opposite to the changes identified in K562 cells, the 
trend of K562 cells and patients' samples are comparable. 
In fact, the data reported for both K562 cells and patients' 
samples come from a relative quantitation analysis, in 
which untreated cells and healthy subjects are used as a 
reference. Therefore, if we compare the amount of mRNA 
within patients' samples during therapy, and we compare 
it with K562 cells' behavior during treatment, we would 
see that responder patients during DFX therapy show a re-
duction of gene expression (therapy vs baseline), and the 
same happens in K562 cells treated with FeCl3  +  DFX 
(as compared with CTRL). In contrast, non-responder pa-
tients during therapy show an increase of gene expression 
(therapy vs baseline), and the same happens in K562 cells 
treated only with FeCl3 (as compared with CTRL).
Interestingly, although tested on a very small number of 
cells and samples, there was an apparent difference in PI-
PLCbeta1/Cyclin D3/PKCalpha localization between baseline 
and therapy, that was also partially confirmed by our analyses 
on K562 cell line. The apparent nuclear localization of inos-
itides during treatment could hint at a specific involvement of 
this signaling pathway during oxidative stress, that could be 
linked to a specific regulation of hematopoietic differentiation 
and needs to be further investigated, first in a larger number 
of patients' cells, then in other in vitro experimental models.
We are indeed aware that in this study we analyzed a 
very small number of MDS patients, and larger studies are 
warranted to confirm these preliminary data. Nevertheless, 
our results show for the first time that the expression of 
PI-PLCbeta1, Cyclin D3 and PKCalpha is directly associated 
with iron-induced oxidative stress and ROS production in 
both MDS and hematopoietic cells. As PI-PLCbeta1 is up-
stream Cyclin D3 and PKCalpha, it could become an import-
ant novel target for the development of specific innovative 
personalized therapies based on the reduction of oxidative 
stress and ROS production. Moreover, PI-PLCbeta1 quantita-
tion could lead to a better comprehension of the mechanisms 
underlying the MDS pathogenesis and become a novel mo-
lecular marker in ICT, possibly allowing the early identifica-
tion of patients likely to be refractory to DFX therapy.
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